静脉注射免疫球蛋白给药后系统性硬化症相关肠假性梗阻快速改善
本文报告3例系统性硬化症合并肌炎重叠综合征患者接受静脉注射免疫球蛋白(IVIG)后胃肠道症状(包括肠假性梗阻)显著且快速改善,并按照PRISMA 2020指南系统综述既往文献,发现既往报告均为回顾性研究且缺乏客观定量短期结局指标;作者认为IVIG似乎是管理系统性硬化症胃肠道症状(包括肠假性梗阻)有前景的治疗选择,理想情况下应在多中心随机安慰剂对照研究中采用可靠定量指标评估短期结局。
要点
- 3例系统性硬化症合并肌炎重叠综合征患者接受IVIG后胃肠道症状(包括肠假性梗阻)显著且快速改善。
- 系统文献综述支持IVIG对系统性硬化症胃肠道表现的有效性和安全性,但既往研究均为回顾性且缺乏客观定量短期结局描述。
- 作者认为IVIG似乎是管理系统性硬化症胃肠道症状(包括肠假性梗阻)有前景的治疗选择,理想情况下应在多中心随机安慰剂对照研究中采用可靠定量指标评估短期结局。
核心结论
- IVIG似乎是管理系统性硬化症胃肠道症状(包括肠假性梗阻)有前景的治疗选择。
- 研究者应更关注短期结局以恰当评估IVIG的治疗获益,理想情况下应在多中心随机安慰剂对照研究中采用可靠定量指标。
研究设计与样本
- 本文报告3例接受IVIG治疗的系统性硬化症合并肌炎重叠综合征患者的胃肠道症状反应。
- 并按照PRISMA 2020指南进行系统文献综述,总结既往关于IVIG对系统性硬化症胃肠道表现疗效的报告。
主要发现
- 病例系列显示IVIG给药后胃肠道症状(包括肠假性梗阻)显著且快速改善。
- 文献综述发现既往报告也支持IVIG对系统性硬化症胃肠道表现的有效性和安全性。
- 既往报告均为回顾性研究,且缺乏对IVIG给药后短期结局的客观定量指标描述。
局限性
- 既往报告均为回顾性研究。
- 既往报告缺乏对IVIG给药后短期结局的客观定量指标描述。
- 作者认为理想情况下应在多中心随机安慰剂对照研究中采用可靠定量指标评估短期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: SSc is an autoimmune disease characterized by excessive fibrosis in multiple organs, including the gastrointestinal (GI) tract. GI symptoms of SSc such as intestinal pseudo-obstruction (IPO) are often refractory to conventional intervention and can result in longer in-hospital stay or even increased mortality. We aimed to summarize the insights to date regarding the efficacy of IVIG against GI symptoms of SSc to unveil what we should focus on in future studies. METHODS: Herein we report the response of GI symptoms in three cases with SSc-myositis overlap who received IVIG administration. We also conducted a systematic literature review to summarize previous reports regarding the efficacy of IVIG upon the GI manifestations of SSc, according to the PRISMA 2020 guideline. RESULTS: The case series demonstrated remarkable and rapid improvement of GI symptoms, including IPO, after IVIG administration. The literature review revealed that previous reports also support the efficacy and safety of IVIG against GI manifestations of SSc. However, they were all retrospective studies and lacking description of the short-term outcome after IVIG administration with objective and quantitative metrics. CONCLUSION: IVIG seems to be a promising therapeutic option for the management of GI symptoms in SSc, including IPO. Investigators should focus more on short-term outcomes to properly assess the therapeutic benefit of IVIG, ideally using reliable quantitative measures in a multicentre randomized placebo-controlled setting.
引用
- Matsuda KM, Yoshizaki A, Kuzumi A, et al. Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration. Rheumatology (Oxford). 2023. PMID: 36825818. doi:10.1093/rheumatology/kead093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。